Examination revealed a well developed young man, alert, cognitivelyintactandwhollynon-psychotic.Theneurological examination wasgrossly intact except for speech andmotor system signs described below. There were dyskinetic move ments ofhis tongue andoccasional involuntary deviation of his tongue to the right on protrusion. Greenwald, 1981; Bond et al, 1982; Ravi et al, 1982; Nevludetal,1983; Gerratt etal,1984). Most cases of TD aremild and non-progressive in nature, although in some patients the symptoms can be severe, persistent and potentially irreversible (Kane et al, 1986). There is great concern within the psychiatric field that TD reflects neurotoxic effects ofchronic neuroleptic drug treatment (Jellinger, 1977).However, there is no conclusive evidence demonstrating structural changes in the central nervous systems (CNS) of patients with TD. In this report we describe a case ofneuroleptic-induced side-effects consisting of choreoathetoid dyskinesia and spastic dysphonia associated with clinical signs and electromyographic signs of muscledenervation.
to the pointoftotal aphonia.Thepatientwouldtry to speak but wasunableto generatetonal sound. He couldconverse only with great difficulty. The patient underwent otolaryn gological and neurological evaluations, which were negative, identifying no organic basis for his speech problem. His Examination revealed a well developed young man, alert, cognitivelyintactandwhollynon-psychotic.Theneurological examination wasgrossly intact except for speech andmotor system signs described below. There were dyskinetic move ments ofhis tongue andoccasional involuntary deviation of his tongue to the right on protrusion. There also were mild involuntarychoreoathetoidmovementsinthedistalupperand lower extremities. Inaddition, hehadafmepostural tremor of hisrightupperextremityandhewasdilfuselyhyperreflexic withplantar flexorresponses.Themostdramaticfeatureof the clinical examination was that the patient was unable to speakand had to struggleto communicate.His sternocleido mastoid and accessorrespiratory muscleswould contract vigorously and his face turn red with effort, but he could emit no sound, not even a whisper, other than the expulsion of air in a manner of speech resembling laryngectomised patients.
His family history was negative for neurological and psychiatric disease. A diagnostic work-up which included laboratory tests (serum chemistries, complete blood count, sedimentationrate, ceruloplasmin, vDRL, ANA, 14, TSH, urinalysis), EEG and CT scan were negative. A tension test and then a sodium amytal interview wereperformed to ruleout myasthema gravis and psychogenicfactors as the causeof the patient's aphoma.
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The therapeutic benefits of neuroleptic drugs are limited by their extensive side-effect profile. Neuro logical adverse effects arethemost prevalent and serious, particularly the syndrome of tardive dyskinesia (TD) (American Psychiatric Association, 1980) . The TD syndrome is characterised by involuntary move ments that most commonly involve the oral-facial lingual regions, butwhichcanoccurinany body region (Burke, 1984) .These movements are character istically choreoathetoid in nature but can manifest themselves inotherformsincluding dystonia, tics and akathisia (Burke, 1984) . Although infrequent, there have been prior reports describing the involve ment of the anatomical structures of respiration (Weiner et al, 1978) , deglutition (Moss and Green, 1982) and speech (Maxwell et al, 1970; Nurnberg & Greenwald, 1981; Bond et al, 1982; Ravi et al, 1982; Nevludetal,1983; Gerratt etal,1984) . Most cases of TD aremild and non-progressive in nature, although in some patients the symptoms can be severe, persistent and potentially irreversible (Kane et al, 1986) . There is great concern within the psychiatric field that TD reflects neurotoxic effects ofchronic neuroleptic drug treatment (Jellinger, 1977) .However, there is no conclusive evidence demonstrating structural changes in the central nervous systems (CNS) of patients with TD. In this report we describe a case ofneuroleptic-induced side-effects consisting of choreoathetoid dyskinesia and spastic dysphonia associated with clinical signs and electromyographic signs of muscledenervation.
Case report
Thepatient is a23-year-old white male whose psychiatric Previous reports of ID involvement of motor speech production have predominantly described disturbances in articulation, e.g. and respiration (Weiner et a!, 1978) . The speech problem in the case described appeared to be purely a disturbance in phonation, indicating the involve ment of the laryngeal musculature. We could find no reports of similar cases of laryngeal dysfunction as a consequence of chronic neuroleptic treatment or manifestation of TD (although acutelaryngeal dystonia has been reported (Solomon,1977) ), suggesting that this is either a rare manifestation of ID or has been undetected and underreported (Aronson, 1971 In addition, the motor cortex projects to and receives input from the basal ganglia via the corticothalamic tract and thalamocortical radiations (Carpenter & Sutin, 1983 ). This enables the structures of the basal ganglia (striatum, putamen,globus pallidus, sub stantia nigra) tomodulate themotoric expression of speech (West, 1971) .
Since neuroleptics are believed to produce neur ological side-effects including ID by their actions in the basal ganglia, it is plausible that this was the basis of the patient's aphonia as well. Patho physiological theories of ID have not adequately explained the syndrome's topographical variability, nor the selective vulnerability of individual patients.
It is presumed, however, that the high frequency of oralâ€"lingualinvolvement in ID is due to its large anatomical representation in the motor cortex (Carpenter & Sutin, 1983 ). If we extend this line of reasoning and postulate that neuroleptics, rather than disturbing basal ganglia functions generally, have selective anatomically specific effects, then differential symptom expression could be a con sequence of which areas are most affected and their correspondence via thalamocoritcal and cortico thalamic tracts with anatomically specific motor cortical areas. Thus a primary drug-induced basal ganglia disturbance could produce symptoms in discrete body regions, including laryngeal dys function, that would be mediated by corticothalamic and corticobulbar tracts. Although highly speculative, this would explain how the laryngeal musculature could be affected, although not why it has so rarely been reported.
The fact that the patient responded well to clozapine and did not redevelop aphonia is also consistent with this hypothesis. Clozapine has been shown to have less potent pharmacological effects in A-9 dopamine neurons in rodents (which correspond to the striatum in humans) than classical neuroleptics (Seeger et a!, 1982) . This is believed in part to be responsible for its inability to induce Parkinsonism and ID.
These findings raise certain important and con An interesting feature of laryngeal musculature innervation is that it is bilateral (the nucleus ambiguous receives both crossed and uncrossed corticobulbar fibres) and normally exhibits hyper neurotisation (innervation of skeletal muscle fibres by more than one motor end-plate), whereas most otherskeletal muscles haveonlyone motor end plateper fibre (Rossi & Cortesina, 1965) . Such overlap and duplication of innervation couldbe the reason for the apparent infrequent involve ment of laryngeal musculature in TD. In such cases, however, where it occurs, it may be very responsive tocholinonumetic treatment. In summary, thiscase illustrates the rare involvement of laryngeal musculature inID and suggests that thepathophysiology ofthis side-effect syndrome originates with CNS basalganglia structures but may also extend to the peripheral neuromuscular systemaswell.
